Search…

Sanofi (SNY.US) initiates clinical trials for TSLP/IL-13 dual antibodies for COPD II/III.

26/09/2025

According to the Wise Finance APP, on September 24th, the global clinical trial registry website showed that Sanofi's TSLP/IL-13 dual-antibody Lunsekimig (SAR443765) has progressed to the II/III phase and has initiated two II/III phase clinical trials (THESEUS and PERSEPHONE) targeting chronic obstructive pulmonary disease (COPD).

Latest

4 m ago

Daysmart Central South Headquarters Settles in Xiangjiang New Area.

8 m ago

Hua Lake International Airport has received authoritative certification for the air transportation of lithium batteries, accelerating the overseas expansion of new energy companies in Hubei Province.

9 m ago

In August, Hubei Province's industrial electricity consumption growth rate ranked first in central China.

9 m ago

National Energy Administration: As of the end of August, China's cumulative installed generating capacity has increased by 18% year-on-year.

9 m ago

The National Energy Administration released data today (September 26) showing that by the end of August, the national cumulative installed power generation capacity reached 3.69 billion kilowatts, an increase of 18.0% year-on-year. Among them, the installed capacity of solar power generation reached 1.12 billion kilowatts, an increase of 48.5% year-on-year; the installed capacity of wind power reached 580 million kilowatts, an increase of 22.1% year-on-year. The total installed capacity of wind and solar power reached approximately 1.7 billion kilowatts. (CCTV News).

See all latest